eXp Realty selects Cloze’s AI-powered real estate platform for CRM of Choice program Supernus to Host Second Quarter 2021 Financial Results Conference Call
ROCKVILLE, Md., July 22, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
PLx Pharma Inc. to Discuss 2021 Second Quarter Financial Results on August 6, 2021 Conference Call and Provide Business Update
SPARTA, N.J., July 22, 2021 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or…
Travere Therapeutics to Report Second Quarter 2021 Financial Results
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced…
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)
Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of…
T2 Biosystems to Report Second Quarter 2021 Financial Results on August 5, 2021
LEXINGTON, Mass., July 22, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering
MIRAMAR, Fla., July 22, 2021 (GLOBE NEWSWIRE) — HCW Biologics Inc. (NASDAQ:HCWB) (the “Company”), an…
Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
— Based on latest analyses, company is revising ADVM-022 development plan to focus on wet AMD…
X4 Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 3, 2021
BOSTON, July 22, 2021 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced…
Codexis to Report Second Quarter 2021 Financial Results on August 5
REDWOOD CITY, Calif., July 22, 2021 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq:CDXS), a leading enzyme…
Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter’s Option to Purchase Additional Shares
BOULDER, Colo., July 22, 2021 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company”…
NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Geographic atrophy is a progressive, irreversible retinal degenerative disease that can lead to blindness, with…
Opiant Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a…
Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
Management to host conference call today at 5:00 pm ET AUSTIN, Texas, July 22, 2021…
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical…
New U Life Opens Japan as an NFR Market
Lehi, Utah, July 22, 2021 (GLOBE NEWSWIRE) — New U Life Corporation, a health supplements…
AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)
PRESS RELEASE AB SCIENCE TO PRESENT RESULTS FROM ITS PHASE III AB09004 STUDY IN MILD…
Sanofi: Information concerning the total number of voting rights and shares – June 2021
Information concerning the total number of voting rights and shares, provided pursuant to article L….
Guerbet: Revenue at June 30, 2021
First-half 2021 revenue Strong recovery across all activities Q2 revenue: €186.8 M (+25.1% at…
Foresight Diagnostics’ PhasED-Seq Circulating Tumor DNA Platform Demonstrates Highly Sensitive Minimal Residual Disease (MRD) Detection in B-Cell Lymphomas
Extensive clinical validation in 678 samples from 213 patients with B-cell malignancies Up to 100-fold…